[{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Stifel","pharmaFlowCategory":"D","amount":"$11.8 million","upfrontCash":"Undisclosed","newsHeadline":"Trevi Therapeutics Announces $11.8 Million Private Placement Priced At-the-Market","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Private Placement","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Trevi Therapeutics","amount2":0.01,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","productSubType":"Narcotic","amount2New":0.01,"dosageForm":"Extended-release Tablet","sponsorNew":"Trevi Therapeutics \/ Stifel","highestDevelopmentStatusID":"9","companyTruncated":"Trevi Therapeutics \/ Stifel"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevi Therapeutics Completes Enrollment for Phase 2b\/3 PRISM Study in Chronic Pruritus in PN","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Trevi Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","productSubType":"Narcotic","amount2New":0,"dosageForm":"Extended-release Tablet","sponsorNew":"Trevi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Trevi Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevi Therapeutics Reports Positive Results from the Ph2b\/3 PRISM Trial of Haduvio\u2122 in the Treatment of Prurigo Nodularis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Trevi Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Trevi Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trevi Therapeutics Announces Multiple Late-Breaking Abstracts Accepted for Presentation at Upcoming Medical Conferences on Analysis of Oral Nalbuphine Extended Release","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Trevi Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Trevi Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Devonian Health Group Announces Peer-Reviewed Publication of Thykamine\u2122 Positive Phase 2 Clinical Trial Results in Journal of Drugs in Dermatology","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Thykamine","moa":"PDE","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Devonian Health Group","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Devonian Health Group \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Devonian Health Group \/ Not Applicable"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Devonian to Present Thykamine\u2122 Phase 2 Clinical Results at the 6th Dermatology Drug Development Summit for Inflammatory Skin Diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Thykamine","moa":"PDE","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Devonian Health Group","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Devonian Health Group \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Devonian Health Group \/ Not Applicable"},{"orgOrder":0,"company":"Legacy Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Legacy Healthcare Announces Positive Top-Line Results from Phase 2\/3 Trial of Coacillium Cutaneous Solution, the First Drug for Children and Adolescents with Moderate and Severe Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Coacillium","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Legacy Healthcare","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"Legacy Healthcare \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Legacy Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AOBiome Therapeutics Granted Composition of Matter Patent for its Clinical Candidate B244","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"B244","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"AOBiome Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AOBiome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"AOBiome Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"TSX Venture Exchange","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Devonian Announces Private Placement of up to $5 Million","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Private Placement","leadProduct":"Thykamine","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Devonian Health Group","amount2":0.01,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"Devonian Health Group \/ TSX Venture Exchange","highestDevelopmentStatusID":"9","companyTruncated":"Devonian Health Group \/ TSX Venture Exchange"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.2 million","upfrontCash":"Undisclosed","newsHeadline":"Devonian Announces Closing of a Private Placement of $1.2 Million","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Private Placement","leadProduct":"Thykamine","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Devonian Health Group","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Devonian Health Group \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Devonian Health Group \/ Undisclosed"},{"orgOrder":0,"company":"Legacy Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Legacy Healthcare Announces EMA Validation of Marketing Authorisation Application (MAA) for Coacillium for the treatment of Moderate and Severe Alopecia Areata in Children and Adolescents","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Coacillium","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Legacy Healthcare","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Spray","sponsorNew":"Legacy Healthcare \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Legacy Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cara Therapeutics: Outcome of KOURAGE-1 Study on Oral Difelikefalin in Notalgia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"CARA Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CARA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"CARA Therapeutics \/ Not Applicable"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Market Place
Reset All
